IFX002 is an advancement of vilobelimab technology, currently in preclinical development. IFX002 is a highly potent anti-complement C5a antibody, binding to the same epitope of the C5a protein than vilobelimab. With a higher humanization grade, altered pharmacokinetic properties and a strong patent position IFX002 is well positioned as life-cycle management project for vilobelimab.
